PortalPublikationenSignificant upgrading affects a third of men diagnosed with ...

Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.

Standard

Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. / Chun, Felix K-H; Briganti, Alberto; Shariat, Shahrokh F; Graefen, Markus; Montorsi, Francesco; Erbersdobler, Andreas; Steuber, Thomas; Salonia, Andrea; Currlin, Eike; Scattoni, Vincenzo; Friedrich, Martin; Schlomm, Thorsten; Haese, Alexander; Michl, Uwe; Colombo, Renzo; Heinzer, Hans; Valiquette, Luc; Rigatti, Patrizio; Roehrborn, Claus G; Huland, Hartwig; Karakiewicz, Pierre I.

in: BJU INT, Jahrgang 98, Nr. 2, 2, 2006, S. 329-334.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Chun, FK-H, Briganti, A, Shariat, SF, Graefen, M, Montorsi, F, Erbersdobler, A, Steuber, T, Salonia, A, Currlin, E, Scattoni, V, Friedrich, M, Schlomm, T, Haese, A, Michl, U, Colombo, R, Heinzer, H, Valiquette, L, Rigatti, P, Roehrborn, CG, Huland, H & Karakiewicz, PI 2006, 'Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.', BJU INT, Jg. 98, Nr. 2, 2, S. 329-334. <http://www.ncbi.nlm.nih.gov/pubmed/16879673?dopt=Citation>

APA

Chun, F. K-H., Briganti, A., Shariat, S. F., Graefen, M., Montorsi, F., Erbersdobler, A., Steuber, T., Salonia, A., Currlin, E., Scattoni, V., Friedrich, M., Schlomm, T., Haese, A., Michl, U., Colombo, R., Heinzer, H., Valiquette, L., Rigatti, P., Roehrborn, C. G., ... Karakiewicz, P. I. (2006). Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU INT, 98(2), 329-334. [2]. http://www.ncbi.nlm.nih.gov/pubmed/16879673?dopt=Citation

Vancouver

Chun FK-H, Briganti A, Shariat SF, Graefen M, Montorsi F, Erbersdobler A et al. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. BJU INT. 2006;98(2):329-334. 2.

Bibtex

@article{1b32ef6543eb469b933cb2f1f81acf6e,
title = "Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.",
abstract = "OBJECTIVE: To explore the rate of significant upgrading from biopsy to radical prostatectomy (RP) specimens in a contemporary cohort, and to develop a prognostic model capable of predicting the probability of significant upgrading, as previous reports indicate that up to 43% of men with low-grade prostate cancer at biopsy will be diagnosed with high-grade cancer at RP. PATIENTS AND METHODS: The study cohort comprised 4789 men (median age 63 years, range 39-82) treated with RP, with available clinical stage, prostate-specific antigen levels, biopsy and RP Gleason sum values. These variables were used as predictors in multivariate logistic regression models (LRMs) addressing the rate of significant Gleason sum upgrading, defined as a Gleason sum increase either from or = 7 or from 7 to > or = 8 between the biopsy and RP specimens. Regression coefficients were used to develop and validate (200 bootstrap re-samples) a nomogram predicting significant biopsy Gleason sum upgrading. RESULTS: Significant biopsy Gleason sum upgrading was recorded in 1349 (28.2%) patients. In multivariate LRMs, all predictors were highly significant (all P <0.001). The bootstrap-corrected accuracy of the nomogram predicting the probability of significant Gleason sum upgrading between biopsy and RP specimens was 75.7%. CONCLUSION: Our nomogram might prove highly useful when the possibility of a more aggressive Gleason variant could change the treatment options.",
author = "Chun, {Felix K-H} and Alberto Briganti and Shariat, {Shahrokh F} and Markus Graefen and Francesco Montorsi and Andreas Erbersdobler and Thomas Steuber and Andrea Salonia and Eike Currlin and Vincenzo Scattoni and Martin Friedrich and Thorsten Schlomm and Alexander Haese and Uwe Michl and Renzo Colombo and Hans Heinzer and Luc Valiquette and Patrizio Rigatti and Roehrborn, {Claus G} and Hartwig Huland and Karakiewicz, {Pierre I}",
year = "2006",
language = "Deutsch",
volume = "98",
pages = "329--334",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

RIS

TY - JOUR

T1 - Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation.

AU - Chun, Felix K-H

AU - Briganti, Alberto

AU - Shariat, Shahrokh F

AU - Graefen, Markus

AU - Montorsi, Francesco

AU - Erbersdobler, Andreas

AU - Steuber, Thomas

AU - Salonia, Andrea

AU - Currlin, Eike

AU - Scattoni, Vincenzo

AU - Friedrich, Martin

AU - Schlomm, Thorsten

AU - Haese, Alexander

AU - Michl, Uwe

AU - Colombo, Renzo

AU - Heinzer, Hans

AU - Valiquette, Luc

AU - Rigatti, Patrizio

AU - Roehrborn, Claus G

AU - Huland, Hartwig

AU - Karakiewicz, Pierre I

PY - 2006

Y1 - 2006

N2 - OBJECTIVE: To explore the rate of significant upgrading from biopsy to radical prostatectomy (RP) specimens in a contemporary cohort, and to develop a prognostic model capable of predicting the probability of significant upgrading, as previous reports indicate that up to 43% of men with low-grade prostate cancer at biopsy will be diagnosed with high-grade cancer at RP. PATIENTS AND METHODS: The study cohort comprised 4789 men (median age 63 years, range 39-82) treated with RP, with available clinical stage, prostate-specific antigen levels, biopsy and RP Gleason sum values. These variables were used as predictors in multivariate logistic regression models (LRMs) addressing the rate of significant Gleason sum upgrading, defined as a Gleason sum increase either from or = 7 or from 7 to > or = 8 between the biopsy and RP specimens. Regression coefficients were used to develop and validate (200 bootstrap re-samples) a nomogram predicting significant biopsy Gleason sum upgrading. RESULTS: Significant biopsy Gleason sum upgrading was recorded in 1349 (28.2%) patients. In multivariate LRMs, all predictors were highly significant (all P <0.001). The bootstrap-corrected accuracy of the nomogram predicting the probability of significant Gleason sum upgrading between biopsy and RP specimens was 75.7%. CONCLUSION: Our nomogram might prove highly useful when the possibility of a more aggressive Gleason variant could change the treatment options.

AB - OBJECTIVE: To explore the rate of significant upgrading from biopsy to radical prostatectomy (RP) specimens in a contemporary cohort, and to develop a prognostic model capable of predicting the probability of significant upgrading, as previous reports indicate that up to 43% of men with low-grade prostate cancer at biopsy will be diagnosed with high-grade cancer at RP. PATIENTS AND METHODS: The study cohort comprised 4789 men (median age 63 years, range 39-82) treated with RP, with available clinical stage, prostate-specific antigen levels, biopsy and RP Gleason sum values. These variables were used as predictors in multivariate logistic regression models (LRMs) addressing the rate of significant Gleason sum upgrading, defined as a Gleason sum increase either from or = 7 or from 7 to > or = 8 between the biopsy and RP specimens. Regression coefficients were used to develop and validate (200 bootstrap re-samples) a nomogram predicting significant biopsy Gleason sum upgrading. RESULTS: Significant biopsy Gleason sum upgrading was recorded in 1349 (28.2%) patients. In multivariate LRMs, all predictors were highly significant (all P <0.001). The bootstrap-corrected accuracy of the nomogram predicting the probability of significant Gleason sum upgrading between biopsy and RP specimens was 75.7%. CONCLUSION: Our nomogram might prove highly useful when the possibility of a more aggressive Gleason variant could change the treatment options.

M3 - SCORING: Zeitschriftenaufsatz

VL - 98

SP - 329

EP - 334

JO - BJU INT

JF - BJU INT

SN - 1464-4096

IS - 2

M1 - 2

ER -